1
|
Petermann R, Bianchi F, Saib L, Ferré N, Francelle N, Oudin O, Chenet C, Mammasse Y, Jallu V, Chaussade A, Cornu A, Dubray L, Mailloux A. Severe neonatal thrombocytopenia due to anti-HPA-4b alloantibodies: Third report described in a Caucasian mother. Transfusion 2024; 64:1167-1170. [PMID: 38693097 DOI: 10.1111/trf.17863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Revised: 03/04/2024] [Accepted: 04/17/2024] [Indexed: 05/03/2024]
Abstract
BACKGROUND Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) results from maternal platelet alloimmunization against paternal antigens inherited by the fetus, most often due to the Human Platelet Antigen (HPA)-1 system in Caucasians. We investigated in 2023, a 30-year-old Caucasian woman Gravida 2 Para 1 who gave birth at 35 weeks of gestation to a male (body weight 2210 g) without signs of bleeding. A severe thrombocytopenia (platelet count at 3 G/L) was discovered incidentally a few hours after delivery in the context of the management of a respiratory distress. The newborn recovered after one platelet concentrate transfusion and normalized his platelet count at Day 5. STUDY DESIGN AND METHODS FNAIT investigation was performed according to guideline recommendations. Platelet genotyping was carried out by multiplex PCR. Maternal serological investigation included Monoclonal Antibody-specific Immobilization of Platelet Antigens method (MAIPA) and Luminex technology. RESULTS Parental and newborn genotyping pointed out an HPA-4 incompatibility between the mother and the newborn and the father. Serological investigation revealed an anti-HPA-4b alloantibody confirming the diagnosis of neonatal alloimmune thrombocytopenia. CONCLUSION We described the third case of anti-HPA-4b alloantibody discovered in a Caucasian mother. This case strengthens the need for reference laboratory to genotype a panel of HPA alleles reflecting local genetic population diversity and for crossmatch of maternal serum with fresh paternal platelets in clinical suspected cases of neonatal alloimmune thrombocytopenia.
Collapse
Affiliation(s)
- Rachel Petermann
- Hospital Saint-Antoine, National Reference Center for Perinatal Hemobiology, Paris, France
- INSERM, UMR_S1134, Paris, France
| | - Frédéric Bianchi
- Hospital Saint-Antoine, National Reference Center for Perinatal Hemobiology, Paris, France
| | - Loubna Saib
- Hospital Saint-Antoine, National Reference Center for Perinatal Hemobiology, Paris, France
| | - Nicolas Ferré
- Hospital Saint-Antoine, National Reference Center for Perinatal Hemobiology, Paris, France
| | - Nathalie Francelle
- Hospital Saint-Antoine, National Reference Center for Perinatal Hemobiology, Paris, France
| | - Olivier Oudin
- Hospital Saint-Antoine, National Reference Center for Perinatal Hemobiology, Paris, France
| | - Christophe Chenet
- Hospital Saint-Antoine, National Reference Center for Perinatal Hemobiology, Paris, France
| | - Yasmine Mammasse
- Hospital Saint-Antoine, National Reference Center for Perinatal Hemobiology, Paris, France
| | - Vincent Jallu
- Hospital Saint-Antoine, National Reference Center for Perinatal Hemobiology, Paris, France
| | - Amélie Chaussade
- Hopital Armand-Trousseau, National Reference Center for Perinatal Hemobiology, Paris, France
| | - Antonin Cornu
- Centre Hospitalier Rives de Seine Service de Neonatologie, Neuilly-sur-Seine, France
| | - Laureline Dubray
- Centre Hospitalier Rives de Seine Service de Neonatologie, Neuilly-sur-Seine, France
| | - Agnès Mailloux
- Hospital Saint-Antoine, National Reference Center for Perinatal Hemobiology, Paris, France
| |
Collapse
|
2
|
Wu G, Zhou Y, Li L, Zhong Z, Li H, Li H, Yu M, Shen W, Ni H. Platelet Immunology in China: Research and Clinical Applications. Transfus Med Rev 2017; 31:118-125. [DOI: 10.1016/j.tmrv.2016.12.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2016] [Revised: 12/01/2016] [Accepted: 12/01/2016] [Indexed: 12/29/2022]
|
3
|
Wu GG. Detection of clinically relevant platelet antibodies in the Asian population. ACTA ACUST UNITED AC 2014. [DOI: 10.1111/voxs.12098] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- G.-G. Wu
- Nanning Institute of Transfusion Medicine; Nanning China
| |
Collapse
|
4
|
Kiyokawa T, Koh Y, Mimura K, Nakayama K, Hosokawa M, Sakuragi M, Morikawa T, Nakao M, Aochi H, Fukumori Y, Kanagawa T, Nagamine K, Kimura T, Tomiyama Y. A case of neonatal alloimmune thrombocytopenia in the presence of both anti-HPA-4b and anti-HPA-5b antibody: clinical and serological analysis of the subsequent pregnancy. Int J Hematol 2014; 100:398-401. [PMID: 24972694 DOI: 10.1007/s12185-014-1620-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2014] [Revised: 06/10/2014] [Accepted: 06/11/2014] [Indexed: 11/30/2022]
Abstract
Neonatal alloimmune thrombocytopenia (NAIT) is induced by maternal alloantibodies raised against fetal platelet antigens inherited from the paternal parent. In contrast to Caucasians, in Asians, predominantly in Japanese, most frequently detected antibodies in NAIT are anti-HPA-4b and anti-HPA-5b. In some NAIT cases multiple alloantibodies are detected. In such cases it is very difficult to determine which antibody is the dominant antibody in NAIT. In this case report, we describe a NAIT case (first sibling) with severe thrombocytopenia and cephalhematoma in the presence of both anti-HPA-4b and anti-HPA-5b antibodies in the maternal serum. We carefully examined titers of anti-HPA antibodies during the subsequent pregnancy with HPA-4b-positive and HPA-5b-negative fetus determined by amniocentesis at gestational week 16. We administered IVIG (1 g/kg/w) to the mother from gestational week 32 to 35. The mother subsequently delivered a second sibling with normal platelet count by cesarean section. Although we could not completely rule out the involvement of anti-HPA-4b, our findings suggested that anti-HPA-5b was implicated in the NAIT in the first sibling.
Collapse
Affiliation(s)
- Tomoko Kiyokawa
- Department of Blood Transfusion, Osaka University Hospital, 2-15 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Hayashi T, Amakishi E, Matsuyama N, Yasui K, Furuta RA, Hori Y, Tanaka S, Fukumori Y, Hirayama F, Inoue M. Establishment of a cell line panel as an alternative source of platelet antigens for a screening assay of anti-human platelet antibodies. Transfus Med 2011; 21:199-204. [PMID: 21208305 DOI: 10.1111/j.1365-3148.2010.01064.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND A panel of platelets expressing various human platelet antigens (HPAs) for a platelet antibody screening assay is difficult to prepare because some antigens are rarely expressed. Therefore, an alternative method without using platelets would be helpful in detecting HPA antibodies. This study describes the establishment of cell lines that stably express specific HPAs and their application for detecting specific antibodies. METHODS Wild-type β3, HPA-1b, -6b, -7b and -7 variant cDNA as well as wild-type αIIb and HPA-3b cDNA were individually co-transduced with wild-type αIIb and β3 cDNA in the K562 cell line. We performed an immunobead monoclonal antibody immobilisation of platelet antigens (MAIPA) assay to evaluate this cell line panel for antibody detection using identified sera containing HPA antibodies, whose specificities had been determined by the mixed passive haemagglutination test. RESULTS AND CONCLUSION Of the 12 sera containing HPA-1a (n = 2), HPA-3a (n = 6), HPA-6b (n = 3) or HPA-7 variant (n = 1) antibodies, all antibodies were detected and determined by our new method, except for two HPA-3a antibodies. One of the two antibodies was also negative for conventional platelet MAIPA, suggesting that the cell line panel might be used as an alternative source of platelet antigens in the MAIPA assay.
Collapse
Affiliation(s)
- T Hayashi
- Japanese Red Cross Osaka Blood Center Department of Biochemistry and Molecular Pathology, Medical School, Osaka City University, Osaka, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Blanchette VS, Johnson J, Rand M. The management of alloimmune neonatal thrombocytopenia. Best Pract Res Clin Haematol 2000; 13:365-90. [PMID: 11030040 DOI: 10.1053/beha.2000.0083] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Neonatal alloimmune thrombocytopenia (NAITP), defined as thrombocytopenia (platelet count < 150 x 10(9)/l) due to transplacentally acquired maternal platelet alloantibodies, occurs in approximately 1 per 1200 live births in a Caucasian population. In such a population, the majority (> 75 percent) of cases are due to fetomaternal incompatibility for the platelet specific alloantigen, HPA-1a (P1A1, Zwa). Incompatibility for the HPA-5b (Bra) alloantigen is the next most frequent cause of NAITP in Caucasians; much less common is NAITP due to incompatibility for HLA, blood group ABO or other platelet-specific antigens. In non-Caucasian populations (e.g. Orientals) HPA-1a incompatibility is a rare cause of NAITP and other alloantigens e.g. HPA-4b (Penb, Yuka) are implicated. The greatest clinical challenge relates to the antenatal management of pregnant women alloimmunized to the HPA-1a (P1A1, Zwa) antigen, and particularly the subset of such women who have a history of a previously affected infant with severe thrombocytopenia and/or intracranial hemorrhage (ICH). The risk of antenatal ICH in the fetus of such women is high enough to merit intervention, either weekly infusion of high-dose intravenous immunoglobulin G (IVIG) with or without corticosteroids given to the mother (the preferred approach in North American centres), or repeated in-utero fetal platelet transfusions (the preferred treatment approach in some European centres). Post-natal management of severely affected infants centres on the rapid provision of compatible antigen-negative platelets harvested from the mother or a phenotyped donor. The value of antenatal screening programs to detect 'at risk' alloimmunized women during pregnancy continues to be debated.
Collapse
Affiliation(s)
- V S Blanchette
- University of Toronto, Hospital for Sick Children, ON, Canada
| | | | | |
Collapse
|
7
|
Lipscomb DL, Bourne C, Boudreaux MK. DNA sequence of the canine platelet beta3 gene from cDNA: comparison of canine and mouse beta3 to segments that encode alloantigenic sites and functional domains of beta3 in human beings. THE JOURNAL OF LABORATORY AND CLINICAL MEDICINE 1999; 134:313-21. [PMID: 10482317 DOI: 10.1016/s0022-2143(99)90212-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The platelet glycoprotein complex alphaIIb beta3 is required for platelet-fibrinogen binding and platelet aggregation. This study was designed to characterize the nucleotide sequence of the canine platelet beta3 gene from cDNA. The nucleotide and deduced amino acid sequences of the canine beta3 gene were 92% and 96% homologous, respectively, with the sequences previously established for the beta3 gene of human beings. Within the beta3 gene, the nucleotide sequence of cDNA prepared from canine platelets shared homology of 89% for the cytoplasmic domain, 93% for the transmembrane domain, 92% for the extracellular domain, 94% for the arginine-glycine-aspartic acid (RGD) binding domain, and 97% for the region associated with Ca2+-dependent stabilization of the alphaIIb beta3 fibrinogen-binding pocket. The deduced amino acid sequence of canine beta3 was 100%, 97%, 96%, and 95% homologous with the cytoplasmic, transmembrane, extracellular, and RGD-binding domains, respectively, and was 100% homologous with the region associated with Ca2+-dependent stabilization of the alphaIIb beta3 fibrinogen-binding pocket of beta3 in human beings. The canine platelet cDNA signal peptide segment of the beta3 gene encodes for 22 amino acids, as compared with 26 amino acids previously reported for human beings. The deduced amino acid sequence of canine beta3 corresponds to the high-frequency allelic form for five of the six alloantigenic sites reportedly associated with human platelets: Leu33Leu40Pro407Arg489Arg636. The apparent amino acid residue in position 143 (Pen alloantigen) of canine platelet beta3 is histidine compared with arginine in human beings. Knowledge of the beta3 gene nucleotide sequence of normal dogs will facilitate the understanding of platelet alphaIIb beta3 structure-function relationships.
Collapse
Affiliation(s)
- D L Lipscomb
- Department of Pathobiology, College of Veterinary Medicine, Auburn University, Alabama 36849, USA
| | | | | |
Collapse
|
8
|
Abstract
Platelet alloantigens can induce the formation of corresponding alloantibodies when exposed to phenotypically negative individuals. These antibodies are responsible for fetal and neonatal alloimmune thrombocytopenia, posttransfusion purpura, passive alloimmune thrombocytopenia and transplantation-associated thrombocytopenia and may contribute to platelet transfusion refractoriness together with HLA antibodies. Besides antibody detection laboratory diagnosis of the clinical syndromes requires alloantigen typing. Furthermore, typed platelet donors are a prerequisite for effective platelet transfusion therapy. Different techniques for phenotyping are well established and easy to perform but they rely on the availability of antisera. Since the molecular genetic background of the clinically most relevant alloantigens has been elucidated during the last years various genotyping methods have been applied to the platelet membrane polymorphisms and thus facilitated widespread platelet alloantigen typing. Generation of antibodies from phage display libraries and of lymphoblastoid cell lines from donors with all genetic variants will allow further developments.
Collapse
Affiliation(s)
- H Kroll
- Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany.
| | | | | |
Collapse
|
9
|
|
10
|
Ohto H, Kato K, Tohyama Y, Okubo M, Morita S, Hattori M, Takasaki K, Sugafuzi M, Imamura S, Sato A, Motoki R. Prenatal determination of human platelet antigen type 4 by DNA amplification of amniotic fluid cells. TRANSFUSION SCIENCE 1997; 18:85-9. [PMID: 10174297 DOI: 10.1016/s0955-3886(96)00081-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
To predict a fetus at risk for neonatal alloimmune thrombocytopenia (NATP) caused by human platelet antigen (HPA)-4 incompatibility, we applied a sequence-specific polymerase chain reaction (PCR-SSP). We were able to determine the HPA-4 genotype of three infants at risk using amniotic fluid cells without the need for fetal blood sampling. The HPA-4 genotypes of amniotic fluid cells determined in this way were completely concordant with the genotype and phenotype of infants' venous blood samples obtained after delivery. Therefore, this technique is also convenient to a fetus at risk in the antenatal management of NATP induced by HPA-4 incompatibility.
Collapse
Affiliation(s)
- H Ohto
- Blood Transfusion Service, Fukushima Medical College
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Abstract
Accepted mechanisms of coagulation are being challenged as new proteins and feedback mechanisms are discovered and evaluated. These new proteins, including tissue factor pathway inhibitor, not only change the way we look at the coagulation mechanism, but also give us potential alternatives in treatment of hemophilia. Gene therapy continues to be a challenging research area, with hemophilia serving as the prototypic hereditary disease target. As acquired disorders of coagulation secondary to immune-mediated events are studied and better understood, our approaches to management of these cases will also change to the benefit of our patients.
Collapse
Affiliation(s)
- M K Boudreaux
- Department of Pathobiology, College of Veterinary Medicine, Auburn University, Alabama, USA
| |
Collapse
|
12
|
Kiefel V. Alloantigene von Thrombozyten. TRANSFUSIONSMEDIZIN 1996. [DOI: 10.1007/978-3-662-10599-3_11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
13
|
Matsui K, Ohsaki E, Goto A, Koresawa M, Kigasawa H, Shibata Y. Perinatal intracranial hemorrhage due to severe neonatal alloimmune thrombocytopenic purpura (NAITP) associated with anti-Yukb (HPA-4a) antibodies. Brain Dev 1995; 17:352-5. [PMID: 8579223 DOI: 10.1016/0387-7604(95)00071-i] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Neonatal alloimmune thrombocytopenic purpura (NAITP) is one of the causes of thrombocytopenia in the newborn period. The thrombocytopenia is caused by maternal transplacental antiplatelet alloantibodies. We report a case of NAITP in a newborn infant having subarachnoid hemorrhage. Examination of platelet antibodies revealed anti-Yukb, that is, human platelet antigen (HPA)-4a incompatibility. Cranial ultrasound and brain magnetic resonance imaging revealed subarachnoid hemorrhage in the temporal region inferior to the cephalohematoma. The lesion seemed to have been sustained during delivery. The patient was treated with high-dose gamma-globulin and several transfusions of random donor platelets and showed a good clinical course. This is the second reported case of NAITP associated with the Yuk antigen system having intracranial hemorrhage.
Collapse
Affiliation(s)
- K Matsui
- Division of Neonatology, Kanawaga Children's Medical Center, Japan
| | | | | | | | | | | |
Collapse
|
14
|
Wang R, Furihata K, McFarland JG, Friedman K, Aster RH, Newman PJ. An amino acid polymorphism within the RGD binding domain of platelet membrane glycoprotein IIIa is responsible for the formation of the Pena/Penb alloantigen system. J Clin Invest 1992; 90:2038-43. [PMID: 1430225 PMCID: PMC443268 DOI: 10.1172/jci116084] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
The human Pena/Penb alloantigen system represents a naturally occurring polymorphism of human platelet membrane glycoprotein (GP) IIIa, and has previously been implicated in the onset of two important clinical syndromes, neonatal alloimmune thrombocytopenic purpura and posttransfusion purpura. To investigate the molecular basis of the polymorphism underlying the Pen alloantigen system, we used the polymerase chain reaction to amplify platelet-derived GPIIIa mRNA transcripts. DNA sequence analysis of amplified GPIIIa cDNAs from nucleotides 161 to 1341 (encompassing amino acid residues 22-414) revealed a G526<==>A526 polymorphism that segregated precisely with Pen phenotype in twelve other individuals examined. This nucleotide substitution results in an Arg (CGA) to Gln (CAA) polymorphism at amino acid 143 of GPIIIa. Interestingly, this polymorphic residue is located within the putative RGD binding site (residues 109-171) of GPIIIa. Platelet aggregation patterns of a Penb/b individual, however, were nearly normal in response to all physiological agonists tested, indicating that this polymorphism does not grossly affect integrin function. Short synthetic peptides encompassing residue 143 were unable to mimic either the Pena or Penb antigenic determinants, suggesting that the Pen epitopes are dependent upon proper folding of the polypeptide chain. Finally, we constructed allele-specific recombinant forms of GPIIIa that differed only at amino acid residues 143. Whereas anti-Pena alloantibodies were able to recognize the Arg143 recombinant form of GPIIIa, anti-Penb antibodies were not. Conversely, anti-Penb alloantibodies were reactive only with the Gln143 isoform of the GPIIIa molecule. It thus appears that amino acid 143 of GPIIIa is not only associated with Pen phenotype, but specifically controls the formation and expression of the Pen alloantigenic determinants.
Collapse
Affiliation(s)
- R Wang
- Blood Research Institute, Blood Center of Southeastern Wisconsin, Milwaukee 53233
| | | | | | | | | | | |
Collapse
|
15
|
Thrombopénie néonatale allo-immune: Identification des anticorps dirigés contre l'antigène PIA1 plaquettaire par immunoblotting. ACTA ACUST UNITED AC 1992. [DOI: 10.1016/s0923-2532(05)80149-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
16
|
Sugano W, Ryo R, Yamaguchi N, Shibata Y. Endoglycosidase H digestion of Yukb (Pena) alloantigen. Thromb Res 1992; 67:167-77. [PMID: 1440520 DOI: 10.1016/0049-3848(92)90136-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
We characterized a platelet specific alloantigen (Yukb). In immunoblotting, anti-Yukb antibody was found to react with both 110 kDa and 96 kDa bands under nonreducing condition. Immunoblotting followed by separation by two-dimensional electrophoresis (isoelectric focusing/SDS-PAGE) showed that the 96 kDa band had a pI of 5.1-5.8, while the 110 kDa band had a pI of 5.2-5.7. The 96 kDa band was identified as glycoprotein (GP) IIIa on the basis of periodic acid Schiff staining, but the 110 kDa band was not characterized. These results implied that it is difficult to determine differences in antigenic epitopes between Yukb and PlA1 antigens by the electrophoresis. Yukb antigen, unlike PlA1 antigen, was partially destroyed by chymotrypsin treatment. Furthermore, endoglycosidase H digestion resulted in loss of the Yukb epitope, while the PlA1 determinant was retained on the three bands with lower molecular weights after endoglycosidase H digestion. The transfer of Yukb antigens recognized by anti-Yukb antibody into the supernatant of platelets treated with endoglycosidase H was also found using mixed passive hemagglutination test. The results indicated that the Yukb epitope might be located to the endoglycosidase H digested N-linked high mannose carbohydrate chains of GP IIIa or hybrid type chains of GP IIIa, which is different from the location of PlA1 epitope.
Collapse
Affiliation(s)
- W Sugano
- Department of Laboratory Medicine, Kobe University School of Medicine, Japan
| | | | | | | |
Collapse
|
17
|
Kekomaki R, Dawson B, McFarland J, Kunicki TJ. Localization of human platelet autoantigens to the cysteine-rich region of glycoprotein IIIa. J Clin Invest 1991; 88:847-54. [PMID: 1715887 PMCID: PMC295471 DOI: 10.1172/jci115386] [Citation(s) in RCA: 61] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
The object of this study was to further localize autoantigenic structures on IIb-IIIa and, if possible, to precisely identify the epitopes recognized by human autoantibodies. In this paper, we identify a 50-kD chymotryptic fragment of IIIa that is recognized by a high percentage of human autoantibodies, typified by the prototype IgG autoantibody RA, which binds to IIIa on intact platelets as well as in an immunoblot assay under nonreduced conditions. Using an immunoblot assay, a carboxy-terminal region of this fragment (33 kD) that contains the cysteine-rich domains of IIIa was found to carry the epitope(s) recognized by the prototype autoantibody RA. The amino-terminal amino acid sequence of the reduced 33-kD fragment, the smallest fragment that retains the RA epitope, is XPSQQDEXSP, and that of the reduced 50-kD fragment is IVQVTFD. This indicates that the 33-kD fragment consists of approximately 175 amino acids beginning at residue 479 and extending at least through residues 636-654, while the 50-kD fragment spans the same region but begins at residue 427. It is apparent that the 33-kD fragment is generated from the 50-kD fragment by additional chymotryptic hydrolysis but remains associated because of the multiple disulfide bonds that are characteristic of this cysteine-rich domain. Sera from 48% of patients with chronic ITP and 2 of 8 patients with acute ITP contain antibodies that bind to the 50-kD fragment in an ELISA. Antibodies of the same specificity are also found in one-third of patients with either secondary immune thrombocytopenia or apparent non-immune thrombocytopenia. We conclude that the 50-kD cysteine-rich region of IIIa is a frequent target of autoantibodies in ITP, but that such antibodies may also be present in cases of thrombocytopenia that cannot be linked to an apparent autoimmune process.
Collapse
Affiliation(s)
- R Kekomaki
- Blood Center of Southeastern Wisconsin, Milwaukee 53233
| | | | | | | |
Collapse
|
18
|
Eisen M, Motum P, Gibson J, Uhr E, Gett M, Kronenberg H, Wylie B. Neonatal alloimmune thrombocytopenia caused by an antibody to the Bak(a) antigen. Pathology 1990; 22:203-5. [PMID: 2091003 DOI: 10.3109/00313029009086663] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
A 31 year old woman was assessed following delivery of her second child affected by neonatal alloimmune thrombocytopenia (NAIT). Antiplatelet antibodies with specificity for Bak(a) were identified in the woman's serum and her platelets were typed as Bak(a) negative whilst her husband's were Bak(a) positive. Unlike the majority of reported anti-Bak(a) antibodies in the literature, this patient's serum contained no contaminating anti-HLA antibodies. This is the first report of NAIT caused by an anti-Bak(a) without co-existing anti-HLA antibodies. An anti-Bak(a) antibody has not previously been reported in Australia. The current status of this antigen system is reviewed.
Collapse
Affiliation(s)
- M Eisen
- N.S.W. Red Cross Blood Transfusion Service, Royal Prince Alfred Hospital, Sydney
| | | | | | | | | | | | | |
Collapse
|
19
|
Affiliation(s)
- C Mueller-Eckhardt
- Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig-University, Giessen, FRG
| | | | | |
Collapse
|
20
|
Abstract
Neonatal alloimmune thrombocytopenia (NAIT) occurs when maternal alloantibodies to antigens present on fetal platelets cause their immune destruction resulting in thrombocytopenia in the newborn infant or fetus. Bleeding may be severe; intracranial haemorrhage and permanent neurological damage are the most serious complications. Despite the severity of the disease, there is often a delay in making the correct diagnosis and instigating appropriate treatment. Recent evidence that NAIT is more common than has previously been recognised, a better understanding of the molecular basis of platelet serology and advances in technology, which have made it possible to take blood samples from fetuses and transfuse them in utero, have all contributed to a growing interest in this condition. In addition, it is exciting to realise that an aggressive approach to the management of established cases and 'at risk' pregnancies can prevent serious neurological sequelae and dramatically improve the outcome for affected infants.
Collapse
Affiliation(s)
- P O Skacel
- Department of Haematology, Northwick Park Hospital, Harrow, Middlesex, UK
| | | |
Collapse
|
21
|
Abstract
The antenatal diagnosis of platelet disorders represents real progress in the early detection of haemorrhagic diseases occurring in the fetus. However, the diagnosis is only possible in some cases during the first trimester of gestation, and not in the first weeks as is the case for other hereditary disorders such as abnormal haemoglobins. This delay can be reduced now that the molecular abnormalities responsible for some platelet disorders have been discovered. If the region of chromosome 17 and the DNA sequence coding for the glycoproteins GP IIb-IIIa were known, this would make possible the recognition of the gene defect responsible for Glanzmann's thrombasthenia. This could also permit the diagnosis of Glanzmann's thrombasthenia at the gene level, i.e. during the first weeks of gestation. However, the use of gene markers could be limited by the fact that a monomorphic clinical expression of Glanzmann's thrombasthenia could correspond to different genetic mutations which can all result in a defect in GP IIb-IIIa synthesis and assembly. If such diagnosis could be made very early, it would only represent real progress if a specific treatment could be applied. New therapeutic approaches to immune thrombocytopenia during pregnancy appear to be possible and can be applied when there is a risk to the fetus, they are still either experimental or anecdotal and there is a real need for a well-designed clinical trial. In all fetal platelet disorders, the risk of fetal death following fetal blood sampling must not be underestimated and very careful, intensive care is necessary after such an investigation. In the absence of a specific therapy, this antenatal diagnosis must be restricted to cases in which the risk of severe haemorrhagic complications are anticipated and where there is a well-documented family history. The patients must be properly informed of all the aspects of the investigation, including the possible risks. As has been the case for other haematological disorders, progress will be made, and we can anticipate that eventually in utero bone-marrow transplantation or gene correction be performed to cure the disease before birth.
Collapse
|
22
|
Abstract
Immune-mediated thrombocytopenias (IMTPs) are frequently-occurring haemostatic disorders in clinical medicine. They may be caused by allo-immunity, autoimmunity, or by drug-induced immune mechanism. All IMTPs are caused by antibodies, which may induce increased platelet destruction but may also hinder platelet function. Many different platelet membrane molecules (i.e. antigens) are involved in the immune processes that play a role in IMTP. Much is already known about the structure of these molecules. Notably the alloantigens involved in alloimmune-mediated thrombocytopenia have been quite well studied. Many of these antigens appear to be polymorphic determinants of adhesion molecules of the integrin superfamily, and are also present on cells other than platelets (endothelial cells, fibroblasts, smooth muscle cells). The methodology for studying platelet antigens and antibodies involved in IMTPs has markedly improved in recent years. This has not only led to better diagnostic tests but also to a better understanding of the immunopathogenesis of these diseases. Platelet immunology is scientifically very much alive, and is expected to remain so in the coming years.
Collapse
|
23
|
Alloantigene von Thrombozyten. TRANSFUSIONSMEDIZIN 1988. [DOI: 10.1007/978-3-662-10601-3_10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
24
|
Furihata K, Nugent DJ, Bissonette A, Aster RH, Kunicki TJ. On the association of the platelet-specific alloantigen, Pena, with glycoprotein IIIa. Evidence for heterogeneity of glycoprotein IIIa. J Clin Invest 1987; 80:1624-30. [PMID: 2445781 PMCID: PMC442432 DOI: 10.1172/jci113250] [Citation(s) in RCA: 89] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Neonatal alloimmune thrombocytopenic purpura associated with a new platelet-specific alloantigen Pena has been reported. We now provide direct evidence that the Pena determinant is associated with glycoprotein (GP) IIIa, but that it is distinct from epitopes that define the PlA system. By ELISA wherein monoclonal antibodies specific for GPIIb (Tab) and specific for GPIIIa (AP3) were used to capture and hold antigens from a platelet lysate prepared under conditions that generate free GPIIb and GPIIIa, anti-Pena reacted with GPIIIa held by AP3 but not with GPIIb held by Tab. In an alternative ELISA where purified GPIIIa from both PlA1-positive and PlA1-negative platelets were used individually as antigen, anti-Pena reacted with both allelic forms of GPIIIa. By radioimmuno-precipitation, anti-Pena precipitated a single surface-labeled membrane protein with electrophoretic characteristics in sodium dodecyl sulfate-polyacrylamide gels, under nonreduced or reduced conditions, identical to those of GPIIIa. By fluorocytometry, platelets from several donors, regardless of PlA phenotype, bound an amount of anti-Pena roughly equivalent to one-half that amount of anti-PlA1 bound by PlA1 homozygous (A1/A1) platelets and roughly equal to that amount of anti-PlA1 bound by PlA1 heterozygous (A1/A2) platelets. Using platelets from donors typed homozygous for PlA1 and Pena in a quantitative indirect binding assay, 14-24,000 molecules of anti-Pena and 41-51,000 molecules of anti-PlA1 were bound per platelet at saturation. Anti-Pena completely inhibited ADP-induced aggregation of Pena-positive platelets, regardless of PlA phenotype. These results indicate that the Pena determinant is associated with GPIIIa but distinct from PlA.
Collapse
Affiliation(s)
- K Furihata
- Blood Center of Southeastern Wisconsin, Milwaukee 53233
| | | | | | | | | |
Collapse
|
25
|
Kunicki TJ, Furihata K, Bull B, Nugent DJ. The immunogenicity of platelet membrane glycoproteins. Transfus Med Rev 1987; 1:21-33. [PMID: 2980263 DOI: 10.1016/s0887-7963(87)70003-0] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- T J Kunicki
- Blood Center of Southeastern Wisconsin, Milwaukee 53233
| | | | | | | |
Collapse
|